Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Inactivated Influenza Vaccine

Clinical medicine profile

Inactivated Influenza Vaccine

Vaccine / immunological product

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
IM / SC / ORAL / ID
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Anaphylaxis to prior dose or component.
  • Live vaccines contraindicated in significant immunosuppression and usually pregnancy.
  • Defer for moderate–severe acute illness.

Precautions

  • Observe 15 minutes post-dose if high anaphylaxis concern.
  • Correct injection technique and site.
  • Report AEFI via national systems.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

One injection per year but children below 9 yrs receiving the injection for the first time is given 2 doses a month a part.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

N/A generally.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

N/A generally.

03 Clinical use

Use, effects & interactions

Indications

  • Active immunization against current existing Influenza.
  • Clinical selection for Inactivated Influenza Vaccine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Vaccine / immunological product.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • Local pain, low-grade fever, myalgia.
  • Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
  • Follow Kenya KEPI / MoH schedules.
  • Never freeze freeze-sensitive vaccines incorrectly.
  • Document batch and site.
  • Separate true contraindications from precautions.
04 Pharmacology

Mechanism & disposition

Stimulates immune system to produce antibodies corresponding to the vaccine antigen.

Stimulates immune system to produce antibo…Vaccines present antigen to the adaptive i…Immunoglobulins provide passive temporary…
Read complete mechanism

Stimulates immune system to produce antibodies corresponding to the vaccine antigen. Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms). Immunoglobulins provide passive temporary immunity.

Onset

Immune response days–weeks

Duration

Months–lifelong (schedule-dependent)

Route

IM / SC / ORAL / ID

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.

Lactation

Most vaccines compatible; live vaccines usually fine for breastfeeding mother.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Vaccine / immunological product)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.